Quantum Immunologics Achieves Major Funding in Support of Ongoing FDA Trials

Tampa, FL, July 15, 2009 – Quantum Immunologics, Inc.

FOR IMMEDIATE RELEASE

Quantum Immunologics, Inc. (QI), a Tampa, Florida company focusing on the research and development of cancer immunotherapies, is pleased to announce that it is receiving equity funding from Mentor Capital, Inc. (Pink Sheets: MNTR) to support its FDA authorized Phase I/II trials on metastatic breast cancer, which are now underway (NCT00879489).

QI’s clinical trial is designed around the use of QI’s proprietary dendritic cell therapy, which employs oncofetal antigen (“OFA”) to recruit the patient’s own immune system to target and attack the cancer cells with the intent to improve patient survivability and quality of life. Each patient will receive three monthly injections of the patient’s own dendritic cells that have been sensitized to OFA. It is anticipated that once the sensitized cells are injected back into the patient, the patient’s T‐cells will locate the OFA found on the patient’s cancer cells, thereby generating an immune response with the goal of killing the cancer cells and preventing further spread of the disease.

In addition to providing $2.2 Million in funding to help support the FDA trials through approximately February 2010, Mentor Capital has agreed to assist QI in funding future strategic stock or cash acquisitions. Mentor will also stand by as a preferred funding source for QI during later stage or additional trials.

Comprehensive information on Mentor Capital, including capital structure detail, can be found at: www.MentorCapital.com. Level II quotes, news, financial information and trading charts may be referenced at www.PinkSheets.com under the trading symbol MNTR.

About Quantum Immunologics

Quantum Immunologics, Inc. (“QI”) is a research‐driven biotechnology company that is pioneering discoveries in immunotherapy science. QI is dedicated to the research, development and production of technologies that focus on the treatments and diagnoses of cancer and other diseases related to the immune system. Leveraging an expansive pipeline of biopharmaceutical innovations, QI remains committed to advancing medicine with the ultimate goal of dramatically improving lives.

For more information about QI and its FDA‐authorized trials, please visit www.quantumimmunologics.com, or contact Investor Relations at (813) 849‐7859.

Forward‐Looking Statements

This press release contains "forward‐looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include, but are not limited to, statements regarding product development, product potential or financial performance. No forward‐looking statement can be guaranteed and actual results may differ materially from those projected. Quantum Immunologics, Inc. undertakes no obligation to publicly update any forward‐looking statement, whether as a result of new information, future events, or otherwise.

Quantum Immunologics, Inc.

2202 N. West Shore Blvd., Suite 200

P.O. Box 20727

Tampa, Florida 33623

Contacts

Quantum Immunologics, Inc.

Timothy Schwiers

813‐849‐7859

Mentor Capital, Inc.

Chet Billingsley, CEO

760‐788‐4700